Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Medical Device

People Briefs: Uroplasty, PCORI, TeraRecon, Pocared Diagnostics

This article was originally published in The Gray Sheet

  • News

Executive Summary

Uroplasty names new chief financial officer. Changes in PCORI leadership. TeraRecon appoints new senior VP. Former BD CEO joins Pocared Diagnostics board.

You may also be interested in...



News In Brief

Industry urges restraint at 510(k) modifications meeting. User fee sequestration unaddressed at House Appropriations Committee markup. More news

People In Brief

Vincent Forlenza becomes chairman of BD. Richard Meelia joins Apollo Endosurgery board. More moves by movers and shakers in the medical device and diagnostics industries.

PCORI Board Eyes Connection Between Health IT Meaningful Use And CER

The inaugural Patient-Centered Outcomes Research Institute board of governors meeting culminated in an interesting suggestion: lining up the institute’s objectives for comparative effectiveness research with those of meaningful use of electronic health records.

Table

View full table

Related Content

Medtech Insight

Topics

Tags:
Medical Device
Latest Headlines

Why Investing In ESG Measures Is Good For Medtech’s Health And Sustainability

IVD DNA Test For Cancer Receives New Regulatory Classification

Minute Insight: Medtronic May Sell Respiratory And Monitoring Units To Private Equity

Stakeholders Give FDA An Earful; Poor Communication, Recall Inefficiency, Patients At Risk

See All
UsernamePublicRestriction

Register

MT032335

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By